Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiyetongmai Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Jilin Tianyao Technology Co., Ltd. for the treatment of ischemic stroke during the convalescent phase. It is specifically indicated for patients exhibiting the TCM pattern of 'blood stasis and collateral obstruction,' a condition characterized by impaired blood flow and meridian blockage following a stroke. The medication is designed to promote blood circulation, resolve stasis, and facilitate neurological recovery. Clinical development has included Phase 1 trials (e.g., CTR20132995) in healthy adult volunteers to evaluate the safety, tolerability, and pharmacokinetics of both single and multiple ascending doses to define the safe clinical dosing range.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiyetongmai Capsule.